Advertisement

Organisation › Details
RA Capital Management L.P.
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital Management to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. *
![]() |
Start | 2001-01-01 established |
![]() |
Industry | private equity |
Industry 2 | LIFE SCIENCES | |
![]() |
Region | Boston, MA |
Country | United States (USA) | |
Street | 200 Berkeley Street 18th Floor | |
City | 02116 Boston, MA | |
Tel | +1-617-778-2500 | |
Address record changed: 2021-03-15 | ||
Basic data | Employees | n. a. |
* Document for �About Section�: PepGen Ltd.. (12/9/20). "Press Release: PepGen Raises $45M Series A". Boston, MA & Oxford. | ||
Record changed: 2021-04-19 |
Advertisement

More documents for RA Capital Management L.P.
- [1] Metagenomi Inc.. (4/7/21). "Press Release: Metagenomi Extends Series A Financing from RA Capital and Welcomes Andrew Levin to Its Board of Directors". Emeryville, CA....
- [2] Eliem Therapeutics, Inc.. (3/25/21). "Press Release: Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders". Seattle, WA & Cambrigde....
- [3] PepGen Ltd.. (2/4/21). "Press Release: PepGen Announces Appointment of James McArthur, Ph.D., as President and Chief Executive Officer". Boston, MA & Oxford....
- [4] PepGen Ltd.. (12/9/20). "Press Release: PepGen Raises $45M Series A". Boston, MA & Oxford....
- [5] Cytek Biosciences Inc.. (11/5/20). "Press Release: Cytek Biosciences Completes Series D Funding Round". Fremont, CA....
- [6] Gibbs, Matthew [CipherBio = SVB]. (9/11/20). "News: Blog – 2020 Biotech Funding Overview"....
- [7] iTeos Therapeutics Inc.. (4/1/20). "Press Release: iTeos Therapeutics Closes $125 Million Series B2 Financing". Cambridge, MA & Gosselies....
- [8] Quench Bio. (1/27/20). "Press Release: Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top